Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

U.S. patent allowed for Vasogen's patient-specific therapy of autoimmune diseases

Dec. 8, 1998

Astra claims novel NOS inhibitors for asthma, rheumatoid arthritis and pain

Dec. 7, 1998

Optimum compound from COX-2 inhibitor series identified by Merck Frosst

Dec. 4, 1998

American Home Products describes preferential COX-2 inhibitors

Dec. 3, 1998

Advisory committee recommends approval of Celebrex for arthritis and further discussions for pain

Dec. 2, 1998

Dual 5-LO/COX inhibitor from Eisai displays potent antiinflammatory efficacy in vivo

Dec. 1, 1998

Results published from phase II trial of Immune Response's rheumatoid arthritis treatment

Dec. 1, 1998

LTA4 hydrolase inhibitors reported in development at Santen

Nov. 30, 1998

FDA advisory committee meets this week to discuss Celebrex NDA

Nov. 30, 1998

Immunex files sBLA for Enbrel as treatment for juvenile rheumatoid arthritis

Nov. 27, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...